Late yesterday, Regeneron issued a press release (largely for investors) with some data about its monoclonal antibody against SARS-CoV-2. The data are scant. The company says that its antibody, REGN-CoV-2, decreased the viral load in some patients and that subsequent medical visits were lower. But there is no data suggesting a change in rates of hospitalization or death so far. We will follow this closely but remind readers that lowering viral loads is not enough; patients must have better outcomes overall for a therapy to be meaningful.